0 avis
Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)
Archive ouverte : Article de revue
Edité par HAL CCSD ; Springer Verlag
International audience